HRT
The warning that scared a generation off HRT is gone.
For more than twenty years, menopausal hormone therapy carried a "black box" warning — the strongest kind the FDA uses. Many women were told no, or decided against it, because of it. In November 2025 that changed.
What the FDA announced
On November 10, 2025, the FDA said it was removing the broad boxed warnings about cardiovascular disease, breast cancer and probable dementia from hormone therapy products (FDA).
Two things did not change:
- The boxed warning about endometrial cancer stays on systemic estrogen-only products — the reason women with a uterus are usually prescribed a progestogen alongside estrogen (FDA).
- The labels recommend starting systemic therapy within 10 years of menopause onset or before age 60 (FDA).
Where the warnings came from
The warnings followed alarming headlines from a large US trial in 2002. The women in that study were, on average, in their sixties — most of them a decade or more past menopause, not in the years when most women seek help for symptoms. Two decades of re-analysis have shown that age and timing matter a great deal to the balance of benefit and risk (Harvard Health).
What it does and doesn't mean
- It doesn't make hormone therapy right for everyone. Your history — including breast cancer, blood clots, stroke and liver disease — still shapes whether it suits you, and there are non-hormonal options too.
- It does mean the conversation is worth having again. If you were told no years ago, the ground has moved.
- Bring your record. How often your symptoms happen and how much they affect you is what a clinician weighs against the risks.
Not sure how to raise it? Read how to talk to your doctor about perimenopause.
This article is education, not medical advice. Decisions about hormone therapy are between you and your clinician.
Menocle keeps count of HRT schedules — patches, cyclical progesterone, days on and off — and lists what you took and from when on your doctor page, so your symptoms can be read against your treatment.
Questions people ask
Did the FDA remove the black box warning on HRT?
Yes. On November 10, 2025 the FDA announced it was removing the broad boxed warnings about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels.
Is there still a warning on estrogen?
Yes. The boxed warning about endometrial cancer remains on systemic estrogen-only products.
When is it recommended to start HRT?
The updated labels recommend starting systemic hormone therapy within 10 years of menopause onset or before age 60. Whether it suits you depends on your history — discuss it with a clinician.
Sources
- FDA — HHS removes misleading FDA warnings on hormone replacement therapy (Nov 10, 2025)
- Harvard Health — FDA removes menopause hormone therapy black box warnings
This article is education, not medical advice. It summarises the published research and guidance above; decisions about your care are between you and your clinician. If a symptom is severe, sudden or worrying, see a doctor.